Jahnke, Zurn Elkay Water Solutions director, sells $848k in stock

Zurn Elkay Water Solutions Corp (NYSE:ZWS) Director Timothy J. Jahnke sold 17,844 shares for approximately $848,482 at an average price of $47.55 on September 12, 2025, via a Rule 10b5-1 plan, with the stock near its 52-week high following a 42% six-month rally. This insider transaction coincides with ZWS reporting robust Q2 2025 results, exceeding EPS ($0.42 vs. $0.36 forecast) and revenue ($445M vs. $424.61M forecast) expectations, driven by 8% organic sales growth. Consequently, analysts have revised price targets upward, with Mizuho increasing its target to $43 (Neutral) and Stifel to $53 (Buy), signaling a positive fundamental outlook for the company.

Analysis

Zurn Elkay Water Solutions (ZWS) presents a picture of strong fundamental performance juxtaposed with a notable insider sale. Director Timothy J. Jahnke sold 17,844 shares for approximately $848,482, but this action is mitigated by two key factors: the transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and the stock is trading near its 52-week high after a 42% gain in six months, making profit-taking a logical move. Furthermore, the director retains a substantial holding of over 490,000 shares both directly and indirectly. This insider activity contrasts with robust Q2 2025 results, where ZWS surpassed expectations with an EPS of $0.42 (versus $0.36 forecast) and revenue of $445 million (versus $424.61 million forecast), driven by strong 8% organic sales growth. This performance has prompted positive analyst revisions, with Stifel increasing its price target to $53.00 (Buy) and Mizuho to $43.00 (Neutral). While Mizuho's target is below the recent trading price of $47.55, the overall sentiment from both fundamental results and analyst actions remains positive.

Key Decisions for Investors

• Investors should view the director's stock sale not as a bearish signal, but as a pre-planned, modest profit-taking event, given the Rule 10b5-1 plan and the director's significant remaining stake.
• Weigh the company's strong operational momentum, demonstrated by its Q2 earnings beat and 8% organic growth, against the stock's recent 42% appreciation, which may indicate that much of the positive news is already reflected in the current price.
• Note the divergence in analyst targets, where Stifel's $53.00 'Buy' rating suggests further upside while Mizuho's $43.00 'Neutral' target implies the stock is fully valued, warranting a careful assessment of the risk/reward profile at current levels.